CRISPR Therapeutics AG (CRSP) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for CRISPR Therapeutics AG, with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -8.11x | -9.07x | -32.28x | -4.86x | 15.24x | -28.94x |
| P/B Ratio | 2.45x | 1.72x | 2.63x | 1.69x | 2.40x | 6.07x |
| P/S Ratio | 1343.50x | 94.87x | 13.40x | 7248.62x | 6.30x | 14043.89x |
| Profitability | ||||||
| Gross Margin | -6537.0% | -215.0% | 64.8% | -25186.7% | 88.9% | -37369.7% |
| Operating Margin | -16191.4% | -1333.0% | -60.1% | -154394.7% | 40.9% | -49295.5% |
| Net Margin | -16569.8% | -1046.4% | -41.5% | -149122.7% | 41.4% | -48520.9% |
| EBITDA Margin | -15636.4% | -1278.0% | -54.8% | -148850.7% | 42.9% | -48018.2% |
| Liquidity | ||||||
| Current Ratio | 13.32x | 22.07x | 17.54x | 15.30x | 20.17x | 18.21x |
| Quick Ratio | 13.32x | 22.07x | 17.54x | 15.30x | 20.17x | 18.21x |
| Leverage | ||||||
| Debt/Equity | 0.21x | 0.12x | 0.13x | 0.13x | 0.09x | 0.04x |
YoY = year-over-year change. Source: FMP..